Skip to main content

Table 3 Independent prognosis analysis of ACT cycles on 3-year CSS

From: The number of cycles of adjuvant chemotherapy in stage III and high-risk stage II rectal cancer: a nomogram and recursive partitioning analysis

 

Non-adjusted

Adjust I

Adjust II

HR (95% CI), p

HR (95% CI), p

HR (95% CI), p

No. of ACT cycles

0.82 (0.72, 0.93), 0.0022

0.84 (0.74, 0.95), 0.0061

0.74 (0.61, 0.89), 0.0016

 0

Ref

Ref

Ref

 1–6

0.28 (0.12, 0.67), 0.0044

0.43 (0.16, 1.15), 0.0929

0.33 (0.11, 0.94), 0.0380

 7–12

0.21 (0.07, 0.61), 0.0042

0.24 (0.08, 0.75), 0.0138

0.20 (0.05, 0.74), 0.0160

  1. Non-adjusted model adjusted for: none
  2. Adjust I adjust for: gender; age; N stage; T stage
  3. Adjust II adjust for: gender; age; N stage; T stage; differentiation; CEA; CA199; PNI; NLR; CCRT; PLN
  4. Abbreviations: PLNR Positive lymph nodes ratio, CA Carcinoma antigen, CEA Carcinoembryonic antigen, CCRT Concurrent chemoradiotherapy, ACT Adjuvant chemotherapy, PNI Prognostic nutritional index, NLR Neutrophil-lymphocyte ratio
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us